EZH2, an epigenetic driver of prostate cancer.
10.1007/s13238-013-2093-2
- Author:
Yeqing Angela YANG
1
;
Jindan YU
Author Information
1. Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
- Publication Type:Journal Article
- MeSH:
DNA Methylation;
genetics;
Enhancer of Zeste Homolog 2 Protein;
Epigenesis, Genetic;
Gene Expression Regulation, Neoplastic;
Humans;
Male;
Molecular Targeted Therapy;
Polycomb Repressive Complex 2;
genetics;
metabolism;
Prostatic Neoplasms;
drug therapy;
genetics;
pathology
- From:
Protein & Cell
2013;4(5):331-341
- CountryChina
- Language:English
-
Abstract:
The histone methyltransferase EZH2 has been in the limelight of the field of cancer epigenetics for a decade now since it was first discovered to exhibit an elevated expression in metastatic prostate cancer. It persists to attract much scientific attention due to its important role in the process of cancer development and its potential of being an effective therapeutic target. Thus here we review the dysregulation of EZH2 in prostate cancer, its function, upstream regulators, downstream effectors, and current status of EZH2-targeting approaches. This review therefore provides a comprehensive overview of EZH2 in the context of prostate cancer.
